You are here


Software for Modeling Delivery and Penetration of Antibody Conjugates

The National Cancer Institute (NCI) seeks parties interested in licensing software for the targeted delivery of anti-cancer agents in solid tumors.
NIH Reference Number
Product Type
  • Drug Design
  • Anti-Cancer Modeling
  • Tumor Delivery
  • Dosing
  • Tumor Penetration
Collaboration Opportunity
This invention is available for licensing.
Description of Technology

The National Cancer Institute (NCI) seeks parties to license software for modeling the targeted delivery of anti-cancer agents in solid tumors.

The software models the permeability and concentration of intravenously administered antibody anti-cancer agent conjugates in solid tumors.  The models can be used to determine optimal dosing regimen of a therapeutic in a particular cancer type.  Thirty factors that affect delivery rates and efficiencies are analyzed as variables in generating the models.

Potential Commercial Applications
  • Drug design
  • Combination therapy
  • Personalized medicine
Competitive Advantages
  • Accurate permeability modeling of anti-cancer therapeutics.
Development Stage

R.K. Jain et al. Delivery of molecular and cellular medicine to solid tumors. [PMID 11259838]

G.M. Thurber et al. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. [PMID 18541331]

Y. Pak et al. Antigen shedding may improve efficiencies for delivery of antibody-based anticancer agents in solid tumors. [PMID: 22562466]

K.C. Chen et al. Modeling recombinant immunotoxin efficacies in solid tumors. [PMID: 18183487]

Patent Status
  • Research Material: NIH will not pursue patent prosecution for this technology
Therapeutic Area
Thursday, June 7, 2018